human bladder cancer cells lines ht1376  (ATCC)

Journal: Diagnostics

Article Title: Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

doi: 10.3390/diagnostics11122270

Figure Lengend Snippet: Up-regulation of SCFA-related genes in bladder urothelial cancer cells after NaB treatment. ( A ) The IC 50 value of about 2.4 mM NaB against HT1376 cells. ( B – D ) Relative mRNA levels of GPR43, GPR109B, and FABP4 in HT1376 cells. All mRNA levels were adjusted relative to the level of glyceraldehyde-3-phosphate dehydrogenase. Data are the mean ± SEM of at least two independent experiments. SCFA, short chain fatty acid; NaB, sodium butyrate. * p < 0.05 and ** p < 0.01.

Article Snippet: Human urinary bladder cancer cell line HT1376 (ATCC CRL-1472) was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques:

Journal: Diagnostics

Article Title: Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

doi: 10.3390/diagnostics11122270

Figure Lengend Snippet: BLCAP and FasL levels in bladder urothelial cells after NaB treatment. ( A ) Relative mRNA level of BLCAP in HT1376 cells. The mRNA level of BLCAP was adjusted relative to the level of glyceraldehyde-3-phosphate dehydrogenase. ( B ) Representative images of BLCAP immunohistochemistry staining. Control mice ( n = 4), without B. pullicaecorum administration; B. pullicaecorum mice ( n = 4), with 1 × 10 7 B. pullicaecorum administration through anal injection. ( C ) Apoptotic rate of HT1376 cells after NaB treatment. ( D ) Relative mRNA level of FasL in HT1376 cells. The mRNA level of CDK1 was adjusted relative to the level of glyceraldehyde-3-phosphate dehydrogenase. Data are the mean ± SEM of at least two independent experiments. ( E ) The protein expression of FasL in HT1376 cells. Data are the mean ± SEM of at least two independent experiments. NaB, sodium butyrate. * p < 0.05.

Article Snippet: Human urinary bladder cancer cell line HT1376 (ATCC CRL-1472) was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Immunohistochemistry, Staining, Control, Injection, Expressing

Journal: Diagnostics

Article Title: Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

doi: 10.3390/diagnostics11122270

Figure Lengend Snippet: Regulation of cell cycles in bladder urothelial cancer cells by NaB. ( A ) Relative mRNA level of CDK1 in HT1376 cells. ( B ) Cell cycle distribution of HT1376 cells after NaB treatment. Data are the mean ± SEM of at least two independent experiments. NaB, sodium butyrate. * p < 0.05.

Article Snippet: Human urinary bladder cancer cell line HT1376 (ATCC CRL-1472) was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques:

Journal: Diagnostics

Article Title: Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

doi: 10.3390/diagnostics11122270

Figure Lengend Snippet: Inhibition of cell growth of bladder urothelial cancer cells by NaB. ( A ) Relative growth of HT1376 cells after NaB treatment. ( B ) Change of BrdU incorporation rate in HT1376 cells after NaB treatment. ( C ) Relative growth of HT1376 cells after conditioned medium treatment. Data are the mean ± SEM of at least two independent experiments. NaB, sodium butyrate. ** p < 0.01 and *** p < 0.001.

Article Snippet: Human urinary bladder cancer cell line HT1376 (ATCC CRL-1472) was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Inhibition, BrdU Incorporation Assay

Journal: Oncology Letters

Article Title: Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells

doi: 10.3892/ol.2017.7269

Figure Lengend Snippet: Analysis of gemcitabine resistance of the bladder cancer cell lines. Bladder cancer cells were treated with gemcitabine for 72 h and cell viability was analyzed using CCK-8. The viability of parental UMUC3 (A) and HT1376 (B) cells was respectively suppressed compared to (A) UMUC3GR and (B) HT1376GR by treatment with gemcitabine in a dose-dependent manner. Values are expressed as means ± standard deviation.

Article Snippet: The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: CCK-8 Assay, Standard Deviation

Journal: Oncology Letters

Article Title: Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells

doi: 10.3892/ol.2017.7269

Figure Lengend Snippet: Proteins with increased expression in gemcitabine-resistant cells identified using iTRAQ proteomic analysis.

Article Snippet: The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Expressing, Multiplex sample analysis, Histone Deacetylase Assay

Journal: Oncology Letters

Article Title: Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells

doi: 10.3892/ol.2017.7269

Figure Lengend Snippet: ECHDC1 protein expression in gemcitabine resistant and sensitive cell lines. (A) ECHDC1 protein expression levels in parental and gemcitabine resistant (GR) cell lines were determined using western blotting. ECHDC1 expression levels were clearly increased in the gemcitabine-resistant cells compared to the gemcitabine-sensitive cells. (B) Immunofluorescence analysis of ECHDC1 expression (red) in the indicated cells. Nuclei were counterstained with Hoechst 33342 (blue). The red signal in the cytoplasm, reflecting ECHDC1 expression, was much stronger in UMUC3GR than in UMUC3 cells.

Article Snippet: The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan).

Techniques: Expressing, Western Blot, Immunofluorescence